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Abstract
Increased production of reactive oxygen and nitrogen species has recently been implicated in the
pathogenesis of cardiac and endothelial dysfunction associated with atherosclerosis, hypertension,
and aging. Oxidant-induced cell injury triggers the activation of nuclear enzyme poly(ADP-ribose)
polymerase (PARP), which in turn contributes to cardiac and vascular dysfunction in various
pathophysiological conditions including diabetes, reperfusion injury, circulatory shock, and aging.
Here, we investigated the effect of a new PARP inhibitor, INO-1001, on cardiac and endothelial
dysfunction associated with advanced aging using Millar's new Aria pressure-volume conductance
system and isolated aortic rings. Young adult (3 months old) and aging (24 months old) Fischer rats
were treated for 2 months with vehicle, or the potent PARP inhibitor INO-1001. In the vehicle-treated
aging animals, there was a marked reduction of both systolic and diastolic cardiac function and loss
of endothelial relaxant responsiveness of aortic rings to acetylcholine. Treatment with INO-1001
improved cardiac performance in aging animals and also acetylcholine-induced, nitric oxide-
mediated vascular relaxation. Thus, pharmacological inhibition of PARP may represent a novel
approach to improve cardiac and vascular dysfunction associated with aging.
Poly(ADP-ribose) polymerase (PARP) is the most abundant nuclear enzyme of eukaryotic
cells. When activated by DNA single-strand breaks, PARP initiates an energy-consuming cycle
by transferring ADP ribose units from NAD+ to nuclear proteins. This process results in rapid
depletion of the intracellular NAD+ and ATP pools, slowing the rate of glycolysis and
mitochondrial respiration, eventually leading to cellular dysfunction and death (reviewed in
Virág and Szabó 2002). PARP can also regulate the expression of various inflammatory
mediators such as inducible nitric-oxide synthase, tumor necrosis factor-α, and intracellular
adhesion molecule-1. Suppression of expression of inducible nitric-oxide synthase, tumor
necrosis factor-α, and intracellular adhesion molecule-1 has been reported in PARP-deficient
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mice and in the presence of pharmacological inhibitors of the enzyme (reviewed in Virág and
Szabó 2002).
Overactivation of PARP represents an important mechanism of tissue damage in pathological
conditions associated with oxidative/nitrosative stress, including myocardial reperfusion
injury, stroke, circulatory shock, autoimmune β-cell destruction, diabetic complications, and
various forms of heart failure (Szabó et al., 1997; Thiemermann et al., 1997; Zingarelli et al.,
1998; Soriano et al., 2001a,b; Pacher et al., 2002a–f; Virág and Szabó 2002; Szabó 2004a).
Activation of PARP also contributes to the development of vascular dysfunction associated
with diabetes, chronic heart failure, and aging (Soriano et al., 2001a,b; Pacher et al., 2002c–
e).
Peroxynitrite, a reactive oxidant species produced from the reaction of nitric oxide and
superoxide, has been established as a pathophysiological relevant endogenous trigger of DNA
single-strand breakage and PARP activation (reviewed in Virág and Szabó 2002). Additional
endogenous triggers of DNA single-strand breakage and PARP activation include hydrogen
peroxide, hydroxyl radical, and nitroxyl anion (reviewed in Virág and Szabó 2002).
There is emerging evidence that the cardiovascular dysfunction associated with aging is related
to the local formation of reactive oxygen and nitrogen species in the myocardium and
vasculature (Inoue et al., 1996; Rodriguez-Martinez et al., 1998; Bejma et al., 2000; van der
Loo et al., 2000; Hamilton et al., 2001; Suh et al., 2001; Csiszar et al., 2002; Lakatta, 2003;
Navarro et al., 2004). The beneficial effect of a phenanthridinone derivative PARP inhibitor,
PJ34, on endothelial dysfunction in aging Wistar rats (Pacher et al., 2002e) has previously been
demonstrated, suggesting that oxygen and nitrogen species-induced intravascular PARP
activation plays an important role in endothelial dysfunction associated with aging (Pacher et
al., 2002e).
Here, we studied the effect of a new potent PARP inhibitor, INO-1001, on the baseline cardiac
performance and systolic and diastolic function at different preloads in aging Fischer-344 male
rats with severely impaired cardiac function, using Millar pressure-volume conductance
catheter system. We have also investigated the changes in vascular reactivity by measuring
acetylcholine-induced, nitric oxide-mediated vascular relaxation in isolated aortic rings.
Materials and Methods
The investigation conformed to the Guide for the Care and Use of Laboratory Animals
published by the U.S. National Institutes of Health (NIH Publication 85-23 revised 1996) and
was performed with the approval of the local Institutional Animal Care and Use Committee.
Animals, Treatment Protocols
Young adult (3 months old) and aging (24 months old) Fischer rats obtained from the National
Institute on Aging were treated for 2 months with vehicle, or the potent isoindolinone-based
PARP inhibitor INO-1001, 30 mg/kg/orally (Inotek Pharmaceuticals, Beverly, MA) (Du et al.,
2003; Khan et al., 2003; Shimoda et al., 2003; Murakami et al., 2004; Szabó et al., 2004b). In
cell-free PARP assay using NAD+ and purified PARP enzyme, INO-1001 inhibited PARP
activity in a dose-dependent manner with an EC50 of 3 nM. The EC50 of the prototypical PARP
inhibitor 3-aminobenzamide was 200 μM. Peroxynitrite- and hydrogen peroxide-induced
oxidation of dihydrorhodamine-123 were unaffected by INO-1001 in the concentration range
up to 10 mM, indicating that the compound does not act as an antioxidant. The chosen dose of
INO-1001 (30 mg/kg/orally) was found to effectively inhibit PARP activation in previous
studies in various tissues including myocardium and vasculature (Du et al., 2003; Khan et al.,
2003; Shimoda et al., 2003; Murakami et al., 2004; Szabó et al., 2004b). Rats were housed two
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to three per cage, fed a standard laboratory diet and water ad libitum, and maintained on a 12-
h light/dark cycle.
Cardiac Remodeling
Following the hemodynamic measurements, the animals were killed by exsanguination
(transection of the inferior vena cava). The heart was removed, and the left and right ventricles
and atria were dissected and weighed. The weight of the ventricles and atria was then
normalized to the body weight. The lungs were also removed and weighed, and wet lung
weights were normalized to body weight and were used as an index of extravascular water lung
accumulation.
Hemodynamic Measurements
Rats were anesthetized with thiopentone sodium (60 mg/kg i.p.) and tracheotomized to
facilitate breathing (Pacher et al., 2002c,d). Animals were placed on controlled heating pads,
and core temperature measured via a rectal probe was maintained at 37°C. A microtip pressure-
volume catheter (SPR-838; Millar Instruments, Inc., Houston, TX) was inserted into the right
carotid artery and advanced into the left ventricle (LV) under pressure control as described
(Pacher et al., 2002c,d, 2003). Polyethylene cannulae (P50) were inserted into the right femoral
artery and vein for measurement of mean arterial pressure. After stabilization for 20 min, the
signals were continuously recorded using an ARIA pressure-volume conductance system
(Millar Instruments Inc.) coupled to a Powerlab/4SP A/D converter (AD Instruments,
Mountain View, CA) at a sampling rate of 1000/s, stored, and displayed on a computer.
The heart rate, maximal left ventricular systolic pressure (LVSP), left ventricular end-diastolic
pressure (LVEDP), mean arterial pressure (MAP), maximal slope of systolic pressure
increment (+dP/dt) and diastolic decrement (−dP/dt), time constant of left ventricular pressure
decay, ejection fraction (EF), stroke volume (SV), cardiac output, and stroke work (SW) were
computed using a cardiac pressure-volume analysis program (PVAN3.2; Millar Instruments,
Inc.) as previously described (Pacher et al., 2003). Stroke volume and cardiac output were
calculated and corrected according to in vitro and in vivo volume calibrations using PVAN3.2
(Pacher et al., 2003), and cardiac output was normalized to body weight [cardiac index (CI)].
Stroke work was also normalized to body weight (SWI). Total peripheral resistance index
(TPRI) was calculated by the equation: TPRI = MAP/CI.
Left ventricular pressure-volume relations were measured by transiently compressing the
inferior vena cava. Indexes of contractility and LV stiffness (preload recruitable stroke work
(PRSW), +dP/dt end-diastolic volume relation (+dP/dt-EDV), and slope of end-systolic and
end-diastolic pressure-volume relations [ESPVR (Emax) and EDPVR] were calculated using
PVAN3.2. Efficiency of left ventricular work (SW/pressure volume area) was also calculated
using PVAN3.2.
The volume calibration of the conductance system was performed as previously described
(Pacher et al., 2003). Briefly, nine cylindrical holes in a block 1-cm deep and with known
diameter ranging from 2 to 11 mm were filled with fresh heparinized whole rat blood. In this
calibration the linear volume-conductance regression of the absolute volume in each cylinder
versus the raw signal acquired by the conductance catheter was used as the volume calibration
formula (Pacher et al., 2003). At the end of each experiment, 50 μl of 15% saline was injected
i.v., and, from the shift of PV relations, parallel conductance volume was calculated by
PVAN3.2 and used for correction for the cardiac mass volume as previously described (Pacher
et al., 2003).
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Vascular Function in Isolated Aortic Rings
Thoracic aorta were removed and cleared from periadventitial fat and cut into 3- to 4-mm width
rings using an operation microscope mounted in organ baths filled with warmed (37°C) and
oxygenated (95% O2, 5% CO2) Krebs' solution (CaCl2, 1.6 mM; MgSO4, 1.17 mM; EDTA,
0.026 mM; NaCl, 130 mM; NaHCO3, 14.9 mM; KCl, 4.7 mM; KH2PO4, 1.18 mM; glucose,
11 mM). Special attention was paid during the preparation to avoid damaging the endothelium.
Isometric tension was measured with isometric transducers (Kent Scientific Corporation,
Litchfield, CT), digitized using a MacLab A/D converter, stored, and displayed on a Macintosh
computer. A tension of 1.5 g was applied, the rings were equilibrated for 60 min, and following
precontraction with epinephrine (10-6 M), relaxation to acetylcholine (10−9 to 3 × 10−4 M) was
measured as previously described (Pacher et al., 2002c–e).
Statistical Analyses
The results are presented as means ± S.E.M. The data were analyzed using a two-factor (age
and treatment) analysis of variance. When the relevant F values of the treatment × age
interaction were significant at the 5% level, pairwise comparisons were made using Dunnett's
test for the effect of treatment in specific age groups and for the effect of age in specific
treatment groups. Statistical significance was ascribed to p values <0.05.
Results
Cardiac Remodeling
Aging was characterized by a significant increase in the weight of the left ventricle and atria,
but not the right ventricle. In addition, lung weight was also significantly increased (Fig. 1).
Treatment with INO-1001 had no significant effect on atrial, left ventricular, and lung weights
(Fig. 1.).
Cardiac Function
As shown in Figs. 2 and 3, aging (A) was characterized by decreased MAP, left ventricular
end-systolic pressure, +dP/dt, −dP/dt, EF, SV, CI, SWI, and heart rate. In contrast, LVEDP
and time constant of left ventricular pressure decay were increased in aging animals, indicative
of diastolic dysfunction. TPRI was also increased in aging rats (Fig. 3). Treatment with
INO-1001 significantly improved SV, CI, and SWI and also decreased LVEDP and the time
constant of left ventricular pressure decay. There was a tendency for the reduction of TPRI by
the drug in aging animals and also improvement of LVSP, mean blood pressure, +dP/dt, and
−dP/dt (Fig. 3.), but it did not reach statistical significance with two-factor analysis of variance
followed by Dunnett's test. In contrast, in young adult control rats, INO-1001 had no effect on
all hemodynamic parameters studied (Fig. 3).
Figure 2 shows representative PV loops from young adult, aging, and aging treated with
INO-1001 rats. The rightward shift of PV loops in aging animals, the decrease in maximal left
ventricular pressure, and +dP/dt indicate depressed cardiac contractility and heart failure.
INO-1001 moderately improved baseline contractile function (Figs. 2 and 3).
Figure 4 shows typical PV loops obtained after inferior vena cava occlusions in aging (middle
panel), aging treated with INO-1001 (lower panel), and young (upper panel) Fischer rats.
Overall results of ESPVR (Emax), PRSW, +dP/dt-EDV, efficiency, and EDPVR are shown in
Fig. 5.
As shown in Figs. 4 and 5, ESPVR was steeper in young animals, suggesting decreased systolic
performance in the aging rats. In contrast, EDPVR was increased in aging rats (Figs. 4 and 5),
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indicating increased end-diastolic stiffness. Treatment with the PARP inhibitor markedly
improved both Emax and EDPVR.
In addition to the above parameters, PV loop recorded at different preloads can be used to
derive other useful systolic function indexes that may be influenced less by loading conditions
and cardiac mass, such as PRSW and +dP/dt-EDV relation (dP/dt-EDV) (Little, 1985; Kass et
al., 1987) (Fig. 5). As shown in Fig. 5, these load-independent indexes of contractility were
largely attenuated in aging animals and markedly improved by PARP inhibition. Efficiency of
left ventricular work was also decreased in aging rats as compared with the young adult ones
and was significantly improved by PARP inhibition (Fig. 5).
Vascular Function
Similarly, to numerous previous studies, our ex vivo experiments demonstrated the loss of
endothelial function in rats with advanced aging indicated by decrease of maximal relaxation
of aortic rings to ACh and rightward shift of the dose-response curve as compared with the
young adult rats (Fig. 6). Pharmacological inhibition of PARP with INO-1001 (2 months)
significantly improved maximal relaxation to ACh in aging animals, however, it had no effect
in young adult rats where relaxation was not impaired (Fig. 6).
Discussion
In this study, we characterized the effects of pharmacological inhibition of PARP with
INO-1001 on cardiac and endothelial dysfunction associated with advanced aging-associated
heart failure using a pressure-volume conductance catheter system and isolated aortic rings in
Fischer rats. The advantage of PV analysis is that it allows the examination of the intact chamber
function independently of loading conditions (Little, 1985; Kass et al., 1987; Nakano et al.,
1990). Using this approach here, we show that treatment with the potent PARP inhibitor,
INO-1001, markedly improves decreased cardiac performance associated with aging.
There is increasing evidence demonstrating an aging-associated development of cardiovascular
dysfunction (Anversa et al., 1989; Capasso et al., 1990; Hatake et al., 1990; Taddei et al.,
1995; Higashi et al., 1997; van der Loo et al., 2000; Hamilton et al., 2001; Boluyt et al.,
2004). The mechanisms responsible for this age-related cardiovascular dysfunction have not
yet been clearly established. This impairment is, at least in part, related to the increased local
formation of reactive oxygen and nitrogen species in the myocardium and vasculature (Inoue
and Inoue, 1996; Rodriguez-Martinez et al., 1998; van der Loo et al., 2000). Superoxide anion
interacts with nitric oxide forming the oxidant peroxynitrite, ONOO, which attacks various
biomolecules, leading—among others—the production of a modified amino acid
(nitrotyrosine) (Beckman and Koppenol, 1996). Although nitrotyrosine was initially
considered a specific marker of peroxynitrite generation, other pathways can also induce
tyrosine nitration (Eiserich et al., 1998). Thus, nitrotyrosine is now generally considered a
collective index of reactive nitrogen species, rather than a specific indicator of peroxynitrite
formation (Halliwell, 1997; Eiserich et al., 1998). Indeed, increased nitrotyrosine formation
was reported in the vasculature of aging animals (van der Loo et al., 2000; Csiszar et al.,
2002).
Oxidative stress accompanied by increased formation of hydrogen peroxide, superoxide anion,
and peroxynitrite are endogenous inducers of DNA single-strand breakage, and DNA single-
strand breakage is the obligatory trigger of PARP activation (reviewed in Virág and Szabó,
2002), which, in turn, may result in rapid depletion of the intracellular NAD+ and ATP pools,
slowing the rate of glycolysis and mitochondrial respiration, and eventually leading to cellular
dysfunction and necrosis. The protective effect of pharmacological inhibition of PARP or lack
of the PARP gene in preventing cardiovascular dysfunction has been demonstrated in
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experimental models of shock, reperfusion injury, diabetes, and heart failure (another condition
where oxidative stress plays a key pathogenetic role) (Szabó et al., 1997; Thiemermann et al.,
1997; Zingarelli et al., 1998; Burkart et al., 1999; Soriano et al., 2001a,b; Pacher et al.,
2002a–f).
The Fischer rat has served as a model to study the mechanisms of the aging-induced changes
in the cardiovascular system (Anversa et al., 1989; Capasso et al., 1990; Boluyt et al., 2004).
In this model, decreased cardiac performance and the development of progressive heart failure
were reported after the age of 20 months (Anversa et al., 1989). Consistently with these
previous results, aging in Fischer rats was associated with decreased +dP/dt, EF, and increased
pulmonary edema. Although +dP/dt has been widely used as a cardiac contractile parameter,
it is well recognized that it is load dependent, especially on changes in preload (Little, 1985;
Kass et al., 1987). EF is also known to be influenced by both preload and afterload and therefore
cannot reliably be used to assess contractile function in models where preload and afterload
are altered. That is why we also determined other PV loop-derived indexes of ventricular
contractility, which are less dependent on loading conditions including Emax, PRSW, and dP/
dt-EDV. All these above-mentioned loading-independent indexes of left ventricular
contractility, similarly to baseline indexes of contractility (+dP/dt, LVSP, and EF), were
markedly decreased indicating severe systolic contractility dysfunction in aging rats.
Pharmacological inhibition of PARP with INO-1001 only moderately improved load-
dependent indexes of contractility (+dP/dt, LVSP, and EF) (Figs. 2 and 3). In contrast, the
treatment remarkably improved all load-independent parameters of left ventricular contractility
(Emax, PRSW, and dP/dt-EDV) indicating improved contractile function.
Impaired cardiac relaxation and increased end-diastolic stiffness observed in aging rats, as
reflected by prolonged time constant of left ventricular pressure decay and increased EDPVR,
was also attenuated by INO-1001 treatment (Fig. 5). Furthermore, INO-1001 also significantly
improved acetylcholine-induced, nitric-oxide mediated, vascular relaxation of isolated aortic
rings. These data are similar to the effect of a phenanthridinone-based PARP inhibitor PJ34,
which also improves endothelium-dependent relaxations in the thoracic aorta of aging animals
(Pacher et al., 2002e).
The current findings are in line with previous studies demonstrating that PARP inhibition
improves cardiac and vascular function in various models of myocardial injury, including acute
ischemia/reoxygenation, as well as various forms of chronic heart failure (diabetes-, drug- and
ischemia-induced) (overviewed in Virág and Szabó, 2002; Szabó et al., 2004a).
In conclusion, our data demonstrate that pharmacological inhibition of PARP with a new,
potent PARP inhibitor, INO-1001, remarkably improves both systolic and diastolic left
ventricular function in an advanced aging-associated heart failure model. In addition,
INO-1001 also improves endothelium-dependent ACh-evoked vascular relaxation of aortic
rings. It is conceivable that the endothelial PARP pathway and the aging-associated heart
failure are interrelated; an impairment of the endothelial function may lead to global or regional
myocardial ischemia, which may secondarily impair cardiac performance. These data indicate
that pharmacological inhibition of PARP may represent a novel approach to improve
cardiovascular dysfunction associated with aging.
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Abbreviations
PARP  
poly(ADP-ribose) polymerase
LV  
left ventricle
LVSP  
left ventricular systolic pressure
LVEDP  
left ventricular end-diastolic pressure
MAP  
mean arterial pressure
+dP/dt  
maximal slope of systolic pressure increment
−dP/dt  
maximal slope of diastolic decrement
EF  
ejection fraction
SV  
stroke volume
SW  
stroke work
CI  
cardiac index
SWI  
SW index
TPRI  
total peripheral resistance index
PRSW  
preload recruitable SW
EDV  
end-diastolic volume
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PV  
pressure volume
ESPVR  
end-systolic pressure-volume relation
EDPVR  
end-diastolic pressure-volume relation
A  
aging
ACh  
acetylcholine
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Fig. 1.
Pharmacological inhibition of PARP (for 2 months) does not affect the cardiac remodeling and
lung edema associated with advanced aging. Left ventricular (LVW), right ventricular (RVW),
atrial (AW) and lung (LungW) weights in young adult (Y), young adult treated with INO-1001
(Y+INO), aging (A), and aging treated with INO-1001 (A+INO) male Fischer rats were
normalized to body weight (BW). Values are mean ± S.E.M. of 6 to 10 experiments in each
group. *, P < 0.05 versus young adult controls.
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Fig. 2.
Representative PV loops (top part) and left ventricular pressure signal (bottom part) from young
adult, aging, and aging treated with INO-1001 rats. Please note that the rightward shift of PV
loops in aging animals, the decrease of maximal left ventricular pressure, and +dP/dt indicate
depressed cardiac contractility and heart failure. INO-1001 moderately improves baseline
contractile function.
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Fig. 3.
Pharmacological inhibition of PARP (for 2 months) improves cardiac dysfunction associated
with advanced aging. Mean blood pressure (mean BP), LVSP, LVEDP, heart rate, +dP/dt and
-dP/dt, EF, time constant of left ventricular pressure decay, stroke volume, SWI, CI, and TPRI
in young adult (Y), young adult treated with INO-1001 (Y+INO), aging (A), and aging treated
with INO-1001 (A+INO) male Fischer rats. Values are mean ± S.E.M. of 6 to 10 experiments
in each group. *, P < 0.05 versus young controls; #, P < 0.05 versus aging.
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Fig. 4.
Pharmacological inhibition of PARP (for 2 months) improves ESPVR and EDPVR in advanced
aging-associated heart failure. Representative PV loops obtained with PV conductance catheter
system at different preloads, showing difference in ESPVR and EDPVR between young adult
(Y), aging (A), and aging treated with INO-1001 (A+INO-1001) rats. The less steep ESPVR
in aging animals (middle panel) compared with control young adult rats (upper panel) indicates
severely decreased contractile function in aging, which is improved by INO-1001 treatment
(lower panel). The steeper EDPVR in aging rats indicates increased end-diastolic stiffness,
which is also improved by INO-1001 treatment.
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Fig. 5.
Pharmacological inhibition of PARP (for 2 months) improves ESPVR (Emax), PRSW, +dP/dt-
EDV, EDPVR, and efficiency in advanced aging-associated heart failure. Overall values of
Emax, PRSW, dP/dt-EDV, EDPV relationships, and efficiency. Values as mean ± S.E.M. of 6
to 10 experiments in each group. *, P < 0.05 versus young adult; #, P < 0.05 versus aging.
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Fig. 6.
Improvement of advanced aging-induced endothelial dysfunction by pharmacological
inhibition of PARP in rats. Acetylcholine-induced endothelium-dependent relaxation. Each
point of the curve represent mean ± S.E.M. of 7 to 10 experiments in vascular rings. *, P <
0.05 versus young adult; #, P < 0.05 versus aging.
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